ASCO conference reports the finding from the randomized phase 2 GROUQ-PCS 9 trial on adding SBRT for oligometastatic CRPC patients

[Graham49]

The study indicates that adding metastasis-directed therapy with stereotactic body radiotherapy (SBRT) to standard systemic therapy for oligometastatic castration-resistant prostate cancer (CRPC) significantly improves oncologic outcomes.

100 patients with oligometastatic CRPC of whom 48 were randomly assigned to receive enzalutamide and androgen deprivation therapy (ADT) and 52 to receive enzalutamide plus ADT and SBRT.

The safety profile of SBRT with enzalutamide plus ADT was consistent with the safety profile of enzalutamide plus ADT.

References:

Niazi T, Saad F, Koul R, et al. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9). Presented at: ASCO GU 2025, February 13-15, San Francisco, California. Poster 22.

[street-air]

why post with no link?

[Graham49 in reply to street-air]

It’s Done now.

doi.org/10.1200/JCO.2025.43...

NCT02685397

[tarhoosier]

I recognize Fred Saad, one of the investigators listed. He has been a prominent researcher in our disease for many years. Montréal based. That raises the value of this research in my eyes.